Liraglutide and Semaglutide Together: What Is Known
Liraglutide and Semaglutide taken together: what each one is, how each is regulated, and what is known about combining them.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 agonistFDA approved (Saxenda, Victoza)LiraglutideGLP-1 receptor agonist sold as Victoza (and Saxenda); the Victoza label covers glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.[13]
GLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[14]GLP-1 & metabolicInteraction notes
Timing, interactions and safety
Evidence for the combination
- STEP 8: head-to-head randomized trial of semaglutide 2.4 mg versus liraglutide 3.0 mg. · PMID 35015037
- Phase 2 randomized trial of semaglutide against liraglutide and placebo for weight loss. · PMID 30122305
- Wegovy label, Indications and Usage (Limitations of Use; not Section 7): concomitant use with any other GLP-1 receptor agonist is not recommended. · FDA label
The studies above describe research settings, not a recommendation to combine them. Ask the prescriber who manages both.
Each component
Side by side
Showing 8 of 10 fields where the two differ. Class, PCAC vote, Jul 2026 are the same or both unknown.
| Field | Liraglutide | Semaglutide |
|---|---|---|
| Class | GLP-1 agonist | GLP-1 agonist |
| Also called | Saxenda, Victoza | sema, Ozempic, Wegovy, Rybelsus, Wegovy pill |
| FDA status | FDA approved (Saxenda, Victoza) | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | [half-life by route] | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | [n] | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses | [dose range] |
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Related tools
Liraglutide vs Semaglutide
Choosing between the two rather than combining them? The comparison lines them up field by field.
What people search
- liraglutide and semaglutide50/mo
- semaglutide and liraglutide40/mo
- semaglutide liraglutide30/mo
- liraglutide semaglutide30/mo
- wegovy saxenda20/mo
- victoza semaglutide20/mo
US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9PubMed search: (liraglutide[tiab] OR Victoza[tiab] OR Saxenda[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA · 2022PMID 35015037Accessed 2 Oct 2026
- 11Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.Lancet (London, England) · 2018PMID 30122305Accessed 2 Oct 2026
- 12WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 13VICTOZA prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 14Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
Found an error? Report a correction.